BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Valatas V, Kolios G, Bamias G. TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity. Front Immunol 2019;10:583. [PMID: 30972074 DOI: 10.3389/fimmu.2019.00583] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Zhang M, Liu S, Xu J, Lv S, Fan Y, Zhang Y, Zhang Y, Wu Y, Su Y, Yu H, Song S, He J, Li H. TNFSF15 Polymorphisms are Associated with Graves’ Disease and Graves’ Ophthalmopathy in a Han Chinese Population. Current Eye Research 2020;45:888-95. [DOI: 10.1080/02713683.2019.1705494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hassan-Zahraee M, Ye Z, Xi L, Baniecki ML, Li X, Hyde CL, Zhang J, Raha N, Karlsson F, Quan J, Ziemek D, Neelakantan S, Lepsy C, Allegretti JR, Romatowski J, Scherl EJ, Klopocka M, Danese S, Chandra DE, Schoenbeck U, Vincent MS, Longman R, Hung KE. Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis. Inflamm Bowel Dis 2021:izab193. [PMID: 34427649 DOI: 10.1093/ibd/izab193] [Reference Citation Analysis]
3 Painter JD, Akbari O. Type 2 Innate Lymphoid Cells: Protectors in Type 2 Diabetes. Front Immunol 2021;12:727008. [PMID: 34489979 DOI: 10.3389/fimmu.2021.727008] [Reference Citation Analysis]
4 Ditrich F, Blümel S, Biedermann L, Fournier N, Rossel JB, Ellinghaus D, Franke A, Stange EF, Rogler G, Scharl M; Swiss IBD Cohort Study Group. Genetic risk factors predict disease progression in Crohn's disease patients of the Swiss inflammatory bowel disease cohort. Therap Adv Gastroenterol 2020;13:1756284820959252. [PMID: 33281934 DOI: 10.1177/1756284820959252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wang L, Zhang GC, Kang FB, Zhang L, Zhang YZ. hsa_circ0021347 as a Potential Target Regulated by B7-H3 in Modulating the Malignant Characteristics of Osteosarcoma. Biomed Res Int 2019;2019:9301989. [PMID: 31950059 DOI: 10.1155/2019/9301989] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
6 Wenxiu J, Mingyue Y, Fei H, Yuxin L, Mengyao W, Chenyang L, Jia S, Hong Z, Shih DQ, Targan SR, Xiaolan Z. Effect and Mechanism of TL1A Expression on Epithelial-Mesenchymal Transition during Chronic Colitis-Related Intestinal Fibrosis. Mediators Inflamm 2021;2021:5927064. [PMID: 34257516 DOI: 10.1155/2021/5927064] [Reference Citation Analysis]
7 Kokkotis G, Bamias G. TL1A as a therapeutic target in inflammatory bowel disease. Expert Rev Clin Immunol 2022. [PMID: 35507314 DOI: 10.1080/1744666X.2022.2074401] [Reference Citation Analysis]
8 Tong X, Zheng Y, Li Y, Xiong Y, Chen D. Soluble ligands as drug targets for treatment of inflammatory bowel disease. Pharmacol Ther 2021;226:107859. [PMID: 33895184 DOI: 10.1016/j.pharmthera.2021.107859] [Reference Citation Analysis]
9 Li H, Christman LM, Li R, Gu L. Synergic interactions between polyphenols and gut microbiota in mitigating inflammatory bowel diseases. Food Funct 2020;11:4878-91. [PMID: 32490857 DOI: 10.1039/d0fo00713g] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
10 Shafiei-Jahani P, Hurrell BP, Galle-Treger L, Helou DG, Howard E, Painter J, Lo R, Lewis G, Soroosh P, Akbari O. DR3 stimulation of adipose resident ILC2s ameliorates type 2 diabetes mellitus. Nat Commun 2020;11:4718. [PMID: 32948777 DOI: 10.1038/s41467-020-18601-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
11 Yu Y, Jiang P, Sun P, Su N, Lin F. Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review). Exp Ther Med 2021;22:693. [PMID: 33986858 DOI: 10.3892/etm.2021.10125] [Reference Citation Analysis]
12 Papara C, Zillikens D, Sadik CD, Baican A. MicroRNAs in pemphigus and pemphigoid diseases. Autoimmun Rev 2021;20:102852. [PMID: 33971341 DOI: 10.1016/j.autrev.2021.102852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Qiang W, Dai Y, Xing X, Sun X. Identification and validation of a prognostic signature and combination drug therapy for immunotherapy of head and neck squamous cell carcinoma. Comput Struct Biotechnol J 2021;19:1263-76. [PMID: 33717423 DOI: 10.1016/j.csbj.2021.01.046] [Reference Citation Analysis]
14 Brochado-Kith Ó, Martínez I, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A, Ángeles Jiménez-Sousa M, Resino S. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients. Front Immunol 2021;12:723196. [PMID: 34497613 DOI: 10.3389/fimmu.2021.723196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Machida K, Aw M, Salter BMA, Ju X, Mukherjee M, Gauvreau GM, O'Byrne PM, Nair P, Sehmi R. The Role of the TL1A/DR3 Axis in the Activation of Group 2 Innate Lymphoid Cells in Subjects with Eosinophilic Asthma. Am J Respir Crit Care Med 2020;202:1105-14. [PMID: 32584596 DOI: 10.1164/rccm.201909-1722OC] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
16 Bamias G, Pizarro TT, Cominelli F. Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab251. [PMID: 34904152 DOI: 10.1093/ibd/izab251] [Reference Citation Analysis]
17 Zhang D, Yang H, Dong X, Zhang J, Liu X, Pan Y, Zhang J, Xu J, Wang Z, Cui W, Dong L. TL1A/DR3 Axis, A Key Target of TNF-a, Augments the Epithelial–Mesenchymal Transformation of Epithelial Cells in OVA-Induced Asthma. Front Immunol 2022;13:854995. [DOI: 10.3389/fimmu.2022.854995] [Reference Citation Analysis]